Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,995 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: carboplatin Clear all
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00023673
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, three-dimensional conformal radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
40
States / cities
Mobile, Alabama • Phoenix, Arizona • Burbank, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 27, 2026, 5:34 PM EDT
Terminated Phase 1 Interventional

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

NCT00811993
View directory record Official record
Conditions
Neoplasms
Interventions
RG1507, RO1507, bevacizumab [Avastin], capecitabine [Xeloda], carboplatin, cetuximab, docetaxel, erlotinib [Tarceva], etoposide, gemcitabine, irinotecan, mFOLFOX6, paclitaxel, pemetrexel, sorafenib, temozolomide, trastuzumab [Herceptin]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Terminated Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

NCT01238133
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 27, 2026, 5:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions
STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
33
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

NCT00334321
View directory record Official record
Conditions
Endometrial Cancer
Interventions
IMRT, Intracavitary vaginal brachytherapy, Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 27, 2026, 5:34 PM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003064
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, etoposide phosphate, paclitaxel, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 27, 2026, 5:34 PM EDT
Active, not recruiting Early Phase 1 Interventional

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

NCT05415709
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Biospecimen Collection, Diagnostic Imaging
Drug · Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299
View directory record Official record
Conditions
Triple Negative Breast Cancer, PD-L1 Negative
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
130
States / cities
Tucson, Arizona • Burbank, California • La Jolla, California + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00003111
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, irinotecan hydrochloride, paclitaxel, neoadjuvant therapy, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00004906
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, pamidronate disodium, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
4
States / cities
Chicago, Illinois • Hackensack, New Jersey • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00006378
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 27, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

NCT06906887
View directory record Official record
Conditions
Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer
Interventions
Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation, Pulsed Low-Dose-Rate (PLDR) Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1Phase 2 Interventional

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

NCT00303849
View directory record Official record
Conditions
Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
Interventions
Carboplatin, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Mannitol, Melphalan, Quality-of-Life Assessment, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 27, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

NCT00268437
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, Pemetrexed, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
90
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

NCT03342911
View directory record Official record
Conditions
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Nivolumab
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

NCT01283334
View directory record Official record
Conditions
Head and Neck Neoplasms, Cancer of the Head and Neck
Interventions
Carboplatin, Cetuximab, RAD001
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

NCT00017251
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
oblimersen sodium, carboplatin, etoposide, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

NCT00091039
View directory record Official record
Conditions
Lung Cancer
Interventions
recombinant fowlpox GM-CSF vaccine adjuvant, recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Terminated No phase listed Observational

Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

NCT00898430
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
Genetic
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00040794
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 27, 2026, 5:34 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 27, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

NCT00153881
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 27, 2026, 5:34 PM EDT